Hjem
Neuro-SysMed (NSM)
Månedlige Neuro-SysMed-seminarer

Neuro-SysMed-seminar – Trond Riise

Velkommen til Neuro-SysMeds månedlige seminarer! Foredragsholder denne gangen er professor Trond Riise, med foredraget Drug-wide prospective study associates thirty-one drug classes with the risk of Parkinson’s disease. Bli med i auditoriet i Armauer Hansens Hus kl. 11:30–13:00 (lunsj fra 11:30–12:00).

brain illustration
Foto/ill.:
Neuro-SysMed / C. Tzoulis

Hovedinnhold

Foredragsholder: Professor Trond Riise

Tittel: Drug-wide prospective study associates thirty-one drug classes with the risk of Parkinson’s disease

Sted: Auditoriet i Armauer Hansens Hus (campus Haukeland universitetssjukehus)

Tidspunkt: Onsdag 18. oktober kl. 11:30–13:00 (lunsj 11:30–12:00).

Registreringslenke: bruk denne lenken

Undervisningsspråk: engelsk

Sammendrag:

The talk is based on the brand new publication Association Between the Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease; A Drug-wide Association Study, by authors Julia Romanowska, Kjetil Bjornevik, Marianna Cortese, Julia A. Tuominen, Magne Solheim, Asieh Abolpour Mofrad, Jannicke Igland, Clemens R. Scherzer and Trond Riise.

Background and Objectives: The incidence rate of Parkinson disease (PD) has been increasing rapidly during the past years. Yet, no treatments exist to prevent or slow the progression of the disease. Moreover, we are unable to detect early disease stages during which intervention with disease-modifying therapies is most likely to succeed. The objective of this study was to perform an agnostic drug-wide association study estimating the association between the use of any of the drugs prescribed in Norway and the subsequent risk of PD. 

Methods: This registry-based cohort study use data from the entire Norwegian population between 2004 and 2019 linked to the Norwegian Prescription Registry, with more than 600 million individual prescriptions. Drug classes were screened according to Anatomical Therapeutic Chemical codes at level 2, corresponding to therapeutic subgroups. We used Cox regression models to estimate hazard ratios (HRs) and 95% CIs for the associations between drug classes and PD risk. All p values were corrected for multiple testing using the false discovery rate. In addition, we conducted sensitivity analyses of exposure definition as well as time-lag and dose-response analyses. 

Results: The study population comprised 3,223,672 individuals, 15,849 of whom developed PD during the follow-up. We identified 31 drug classes that were statistically significantly associated with PD risk in Norway during the follow-up. Drugs acting on the renin-angiotensin system (HR 0.92, 95% CI 0.89–0.95), corticosteroids for systemic use (0.88, 95% CI 0.84–0.93), and vaccines (0.89, 95% CI 0.82–0.96) were associated with a decreased risk of PD even up to 10 years before PD onset. Drug classes used to treat symptoms related to prodromal signs of PD, such as constipation, urological issues, and depression, were associated with an increased risk of subsequent diagnosis of PD with HRs of 1.6 (95% CI 1.49–1.73), 1.48 (1.42–1.53), and 1.94 (1.87–2.01), respectively. 

Discussion: This drug-wide study identified 31 drug classes that were associated with the PD risk change. It reveals the links of renin-angiotensin system medications, vaccines, and corticosteroids with PD risk and suggests that monitoring drug usage using pharmacoepidemiology may allow identifying individuals with prodromal PD.